Reneo Pharmaceuticals, Inc. (RPHM)

Market Cap	218.19M
Revenue (ttm)	n/a
Net Income (ttm)	-67.43M
Shares Out	33.31M
EPS (ttm)	-2.37
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	761,629
Open	6.45
Previous Close	6.34
Day's Range	6.29 - 6.75
52-Week Range	1.79 - 11.30
Beta	0.91
Analysts	Strong Buy
Price Target	27.67 (+322.44%)
Earnings Date	Nov 13, 2023

About RPHM

Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases. Its lead product candidate is REN001, a potent and selective agonist of the peroxisome proliferator-activated receptor delta that is in clinical development for genetic mitochondrial diseases comprising primary mitochondrial myopathies and long-chain fatty acid oxidation disorders. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Irv...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 9, 2021
• Employees: 55
• Stock Exchange: NASDAQ
• Ticker Symbol: RPHM

Analyst Forecast

According to 4 analysts, the average rating for RPHM stock is "Strong Buy." The 12-month stock price forecast is $27.67, which is an increase of 322.44% from the latest price.

Price Target

$27.67

(322.44% upside)

Analyst Consensus: Strong Buy